Gerardo Alfonso CORZO BURGUETE,Lourival Domingos POSSANI POSTAY,Ernesto ORTIZ SURI,Santos RAMÍREZ CARRETO,Juana María JIMÉNEZ VARGAS,Baltazar BECERRIL LUJÁN
申请号：
MX2015008582
公开号：
MX2015008582A
申请日:
2015.07.01
申请国别(地区):
MX
年份:
2017
代理人:
摘要：
The present invention refers to two novel synthetic peptides without disulfide bridges, cloned, synthesized, identified and characterized, also referring to the design of two novel variants of the same. The parental peptides were obtained from the total RNA obtained from the venom glands of the Mexican scorpion Vaejovis punctatus, the invention also referring to the use thereof as an antibiotic agent. These peptides may be produced by a chemical synthesis or by techniques of the recombinant RNA and are known in the present invention as: VpAmp1.0, VpAmp2.0, VpAmp1.1 and VpAmp2.1 (SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4, respectively). The invention comprises their use as antibiotics for controlling bacterial infections, particularly multidrug-resistant Mycobacterium tuberculosis strains and other pathogen bacteria, selected in order to represent the groups of different Gram (-) and Gram (+) pathogens and a yeast group, some of them known by their elevated virulence o r by their resistance to commercial antibiotics, also referring to the pharmaceutical compositions that comprise said peptides, which may be used as a unique antibiotic agent or in combination with commercial antibiotics.La presente invención se refiere a dos nuevos péptidos sintéticos sin puentes disulfuro, clonados, sintetizados, identificados y caracterizados, también se refiere al diseño de dos nuevas variantes de los mismos. Los péptidos parentales se obtuvieron a partir de ARN total obtenido de las glándulas de veneno del alacrán mexicano Vaejovis punctatus, y su uso como agentes antibióticos. Estos péptidos pueden ser producidos por síntesis química o por técnicas del ADN recombinante y son denominados en la presente invención como: VpAmp1.0, VpAmp2.0, VpAmp1.1 y VpAmp2.1 (SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 y SEQ ID NO: 4, respectivamente). La invención comprende su uso como antibióticos para el control de infecciones bacterianas, particularmente cepas multidrogo resistent
